Compare PFIS & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFIS | STTK |
|---|---|---|
| Founded | 1905 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 589.6M | 538.3M |
| IPO Year | 1998 | 2020 |
| Metric | PFIS | STTK |
|---|---|---|
| Price | $56.08 | $6.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $56.00 | $10.00 |
| AVG Volume (30 Days) | 61.2K | ★ 506.4K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | ★ 493.94 | 53.02 |
| EPS | ★ 1.47 | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $5.85 | N/A |
| P/E Ratio | $39.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $43.77 | $0.71 |
| 52 Week High | $59.86 | $8.33 |
| Indicator | PFIS | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 42.49 |
| Support Level | $49.34 | $5.85 |
| Resistance Level | $59.02 | $6.81 |
| Average True Range (ATR) | 2.08 | 0.59 |
| MACD | -0.21 | -0.11 |
| Stochastic Oscillator | 52.84 | 17.37 |
Peoples Financial Services Corp is a bank holding company operating through its subsidiaries. The bank provides a full range of financial services. Its products and services include checking accounts, business accounts, savings accounts, loan products, money market accounts, mortgages, chip-enabled debit cards, credit card processing, equipment finance, working capital lines of credit, and construction loans, and visa master card and advisory services. Its loan portfolio includes Commercial loans, which consist of commercial, commercial real estate, municipal, and other related tax-free loans; and retail loans, which include residential real estate and other consumer loans. The company mainly operates in the United States in Pennsylvania.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.